Why HER3 Is the Critical Vulnerability After EGFR TKI Failure

HER3 (ERBB3) is a near-universally expressed receptor tyrosine kinase in EGFR-mutant non-small cell lung cancer (NSCLC), and its expression is frequently amplified when tumour cells are subjected to the selective pressure of EGFR tyrosine kinase inhibitor (TKI) therapy—including the current standard-of-care third-generation agent osimertinib. This upregulation is not coincidental: HER3 heterodimerises with HER2 and EGFR to sustain downstream PI3K/AKT signalling even when the primary EGFR driver is pharmacologically blocked, providing tumour cells with an adaptive escape route that is largely independent of the specific resistance mutation acquired.

Unlike HER2 amplification or MET amplification—resistance mechanisms that affect only a subset of post-osimertinib patients—HER3 overexpression is a broadly distributed phenotype across the EGFR-mutant NSCLC population. This broad prevalence is precisely what makes HER3 an attractive therapeutic target: a drug that works regardless of which specific resistance alteration is present has a substantially larger addressable patient population than one requiring a companion diagnostic for a rare resistance mutation.

The therapeutic rationale for targeting HER3 with an antibody-drug conjugate (ADC) rather than a small-molecule inhibitor or naked antibody rests on HER3’s biology: unlike HER2, HER3 has minimal intrinsic kinase activity, making small-molecule kinase inhibition largely ineffective. An ADC approach—using the antibody to deliver a cytotoxic payload directly to HER3-expressing cells—sidesteps this limitation entirely, exploiting receptor expression as a homing mechanism rather than a catalytic target. According to data indexed by ClinicalTrials.gov, HER3-directed ADC programmes have expanded rapidly since 2020, reflecting growing consensus on this approach’s validity.

The DXd ADC Platform: Engineering Selectivity and Potency

Patritumab deruxtecan’s therapeutic profile is inseparable from Daiichi Sankyo’s proprietary DXd ADC platform—the same technology underpinning trastuzumab deruxtecan (T-DXd, Enhertu) and datopotamab deruxtecan (Dato-DXd). The platform combines three engineered components: a tumour-targeting antibody, a cleavable tetrapeptide-based linker, and a topoisomerase I inhibitor payload (an exatecan derivative, DXd) with a drug-to-antibody ratio (DAR) of approximately 8.

The high DAR of approximately 8 is a distinguishing feature of the DXd platform compared to earlier ADC technologies such as those used in ado-trastuzumab emtansine (T-DM1), which carries a DAR of approximately 3.5. A higher DAR means more payload molecules per antibody, increasing cytotoxic potency per binding event. Crucially, the DXd linker is designed to be stable in circulation but cleaved efficiently in the acidic, protease-rich lysosomal environment of tumour cells following receptor-mediated internalisation—a balance that reduces off-target toxicity while maximising intracellular drug release.

The membrane-permeable nature of the released DXd payload also enables a “bystander effect”: DXd diffuses from HER3-positive cells into adjacent HER3-negative cells within the tumour microenvironment, potentially addressing tumour heterogeneity and antigen-low subpopulations. This property is considered clinically meaningful in solid tumours where antigen expression is heterogeneous, as documented in research published by Nature and other peer-reviewed oncology journals.

HERTHENA-Lung01 and the Clinical Case for HER3-DXd

The pivotal clinical evidence for patritumab deruxtecan in EGFR-mutant NSCLC comes primarily from the HERTHENA-Lung01 trial—a Phase II, open-label, single-arm study enrolling patients who had progressed on at least one EGFR TKI (including osimertinib) and platinum-based chemotherapy. This heavily pre-treated population represents one of the most clinically challenging settings in thoracic oncology, where available options are limited and response rates to subsequent therapies are typically low.

“In a population that has exhausted EGFR TKI and platinum chemotherapy, a HER3-directed ADC that delivers responses regardless of the specific resistance mechanism acquired represents a paradigm shift in post-TKI sequencing strategy.”

HERTHENA-Lung01 demonstrated clinically meaningful objective response rates and durable progression-free survival in this post-TKI, post-chemotherapy population, supporting regulatory submissions to the US Food and Drug Administration (FDA) and other agencies. The trial’s design as a single-arm Phase II study—rather than a randomised controlled trial—reflects both the urgency of addressing an unmet medical need and the statistical confidence that the observed response rates substantially exceed historical benchmarks for this indication. The FDA has historically granted accelerated approval to oncology agents demonstrating such signals in single-arm trials, as documented in FDA guidance on accelerated approval pathways.

Beyond HERTHENA-Lung01, Daiichi Sankyo and AstraZeneca are evaluating patritumab deruxtecan in earlier treatment settings—including combinations with osimertinib in the first-line and second-line settings (HERTHENA-Lung02 and related trials)—reflecting a strategy to move the drug earlier in the treatment sequence if confirmatory data support it. This earlier-line expansion is the hallmark of a maturing ADC programme with strong mechanistic rationale, mirroring the trajectory of trastuzumab deruxtecan in HER2-positive breast cancer.

The Patent Race: Layered IP Strategy in HER3-Directed ADCs

The intellectual property architecture protecting patritumab deruxtecan is a multi-layered strategy typical of best-in-class ADC programmes, designed to maximise effective market exclusivity well beyond any single patent’s expiry. Understanding this structure is essential for competitive intelligence professionals and R&D strategists evaluating the HER3-directed ADC space.

Layer 1: Composition-of-Matter Patents

The foundation of HER3-DXd’s patent estate comprises composition-of-matter patents covering the patritumab antibody itself, the DXd linker-payload system, and the conjugated ADC molecule. These patents, filed by Daiichi Sankyo and its predecessors (including U3 Pharma, from which the patritumab antibody was derived), represent the strongest form of IP protection because they cover the physical molecule regardless of its therapeutic application. Patent offices including the USPTO and the European Patent Office (EPO) have granted protection across major markets.

Layer 2: Method-of-Treatment Patents

Method-of-treatment patents extend protection to the specific therapeutic use of HER3-DXd in EGFR-mutant NSCLC—covering dosing regimens, patient selection criteria (including HER3 expression thresholds), and combination therapy approaches. These patents are particularly valuable in jurisdictions where composition-of-matter protection may be narrower or where biosimilar/biobetter entry is anticipated after primary patent expiry.

Layer 3: Manufacturing and Process Patents

ADC manufacturing is inherently complex: conjugation chemistry, linker attachment site control, DAR distribution, and formulation are all areas where proprietary process innovations can be independently patented. Daiichi Sankyo’s DXd platform benefits from process patents that create additional barriers to generic or biosimilar replication, even after composition-of-matter patents expire.

Competitors seeking to develop HER3-directed ADCs must navigate not only Daiichi Sankyo’s antibody patents but also the broader DXd linker-payload estate—which is shared across the trastuzumab deruxtecan, datopotamab deruxtecan, and patritumab deruxtecan programmes. This creates a patent thicket around the DXd payload technology that significantly raises the cost and complexity of ADC development for any company seeking to use a similar linker-payload system, as assessed by patent analytics platforms including PatSnap.

Daiichi Sankyo and AstraZeneca: A Collaboration Reshaping Oncology ADCs

The strategic partnership between Daiichi Sankyo and AstraZeneca, announced in 2023, is one of the largest oncology collaborations in pharmaceutical history—valued at up to approximately $6.9 billion including upfront payments and milestone payments across three DXd ADC assets: trastuzumab deruxtecan, datopotamab deruxtecan, and patritumab deruxtecan. The structure of the deal assigns AstraZeneca co-development and co-commercialisation rights outside Japan, while Daiichi Sankyo retains manufacturing control and leads R&D operations.

“The Daiichi Sankyo–AstraZeneca collaboration, valued at up to $6.9 billion across three DXd ADC assets, represents a structural bet that the DXd platform will become the dominant ADC technology across multiple solid tumour indications.”

For patritumab deruxtecan specifically, AstraZeneca’s involvement accelerates global regulatory submissions, expands clinical trial capacity, and provides commercial infrastructure in markets where Daiichi Sankyo has limited oncology presence—particularly in the United States and Europe. The collaboration also enables cross-indication data sharing: insights from trastuzumab deruxtecan’s experience in breast and gastric cancer inform HER3-DXd’s clinical and regulatory strategy in lung cancer.

From a competitive intelligence perspective, the collaboration creates a formidable combined entity in the ADC space. AstraZeneca’s existing NSCLC franchise—anchored by osimertinib (Tagrisso)—provides a natural commercial synergy with HER3-DXd: physicians already prescribing osimertinib in the first-line EGFR-mutant NSCLC setting are the same oncologists who would subsequently prescribe HER3-DXd upon disease progression. This sequential prescriber relationship is a significant commercial advantage that pure-play ADC companies without an established NSCLC presence cannot easily replicate. The global oncology ADC market, tracked by organisations including the IQVIA Institute for Human Data Science, is projected to exceed $30 billion by 2030, with lung cancer ADCs representing a major growth driver.

Competitive Landscape: HER3-DXd Versus Emerging ADC Rivals

Patritumab deruxtecan currently occupies the leading position in HER3-directed ADC development for NSCLC, but the competitive landscape is evolving as multiple pharmaceutical companies recognise the therapeutic and commercial opportunity in this space. Understanding the competitive dynamics requires distinguishing between direct HER3-directed competitors and indirect competition from other ADC targets active in NSCLC.

Direct HER3-Directed Competitors

Several companies have initiated HER3-directed ADC programmes that could eventually compete with patritumab deruxtecan, including candidates from Kelun-Biotech, Byondis, and others using alternative antibodies or linker-payload systems. However, none of these programmes has yet reached the Phase II/III stage in NSCLC, leaving patritumab deruxtecan with a substantial first-mover advantage in clinical maturity and regulatory standing. The patent barriers around the DXd payload technology mean these competitors must use alternative payloads, which introduces additional uncertainty about whether they can match HER3-DXd’s clinical profile.

Indirect Competition: Other ADC Targets in NSCLC

The more immediate competitive pressure on patritumab deruxtecan comes from other ADC targets active in NSCLC—particularly TROP2 (datopotamab deruxtecan) and HER2 (trastuzumab deruxtecan). Because these agents share the DXd payload platform, the clinical question is not which payload is superior but which tumour antigen provides the optimal targeting selectivity and patient selection strategy in post-EGFR TKI NSCLC. HER3-DXd’s advantage is the breadth of HER3 expression—which does not require a companion diagnostic for a rare mutation—whereas HER2-directed T-DXd in NSCLC is limited to the approximately 3% of patients with HER2 mutations or amplifications. WIPO’s patent landscape reports, available at WIPO, document the accelerating pace of ADC patent filings across all major oncology targets since 2018.